Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 11/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391952 | 0.87 | CHRNA7 (0.66) | CHRNA7CHRNB4CHRNA3NPC1RAB9A | |
| SCHEMBL12274238 | 0.85 | CHRNA7 (0.63) | CHRNA7CHRNB4CHRNA3NPC1RAB9A | |
| SCHEMBL388683 | 0.83 | CHRNA7 (0.66) | CHRNA7CHRNB4CHRNA3NPC1MAPT | |
| SCHEMBL1396004 | 0.83 | CHRNA7 (0.66) | CHRNA7CHRNB4CHRNA3NPC1MAPT | |
| Fumaric Acid SCHEMBL391501 | 0.79 | CHRNA7 (0.55) | CHRNA7CHRNB4CHRNA3NPC1RAB9A | |
| SCHEMBL1688975 | 0.79 | CHRNA7 (0.79) | CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1689258 | 0.78 | CHRNA7 (0.66) | CHRNA7CHRNB4CHRNA3NPC1MAPT | |
| SCHEMBL1395946 | 0.78 | CHRNA7 (0.65) | CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1689175 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3NPC1RAB9A | |
| SCHEMBL18016318 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112078-A1 | NOVEL OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2011-05-12 | — | — | US | claimed |
| US-20110112078-A1 | NOVEL OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112078-A1 | NOVEL OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE | CHRNA3, CHRNA6, CHRNA7 | CHRNA7 3/4885CHRNB4 12/4885CHRNA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.